Elanco Q2 revenue $1.177B down 8%; cuts full-year guidance on macro headwinds

Elanco Animal Health Inc

2022-Q2 EPS reported $0.05 revenue$2,402,000,000

Q2 revenue $1,177M (-8% reported, -4% constant currency); Pet Health $612M (-11%), Farm Animal $553M (-2%).
Reported EPS $(0.04), adjusted EPS $0.36; adjusted EBITDA $300M (25.5% margin) vs $291M prior year.
Full-year revenue guidance cut to $4,465-$4,550M from $4,700-$4,755M; adjusted EPS now $1.06-$1.13 vs $1.15-$1.21.
Net leverage 5.3x; target ~5.0x by year-end; 60% gross margin and 31% adjusted EBITDA timeline extended.
In-licensed feline diabetes product under FDA review; Zorbium launched; pipeline on track for two blockbuster submissions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.